EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression
Neuro-Oncology · 2023
DOI: 10.1093/neuonc/noad128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Arthur R Wolin und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Colorado Anschutz Medical Campus (AMC), Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Medulloblastoma, Cerebellar Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Background
Medulloblastoma is the most common pediatric brain malignancy. Patients with the Group 3 subtype of medulloblastoma (MB) often exhibit MYC amplification and/or overexpression and have the poorest prognosis. While Group 3 MB is known to be highly dependent on MYC, direct targeting of MYC remains elusive.
Methods
Patient gene expression data were used to identify highly expressed EYA2 in Group 3 MB samples, assess the correlation between EYA2 and MYC, and examine patient survival. Genetic and pharmacological studies were performed on EYA2 in Group 3 derived MB cell models to assess MYC regulation and viability in vitro and in vivo.
Results
EYA2 is more highly expressed in Group 3 MB than other MB subgroups and is essential for Group 3 MB growth in vitro and in vivo. EYA2 regulates MYC expression and protein stability in Group 3 MB, resulting in global alterations of MYC transcription. Inhibition of EYA2 tyrosine phosphatase activity, using a novel small molecule inhibitor (NCGC00249987, or 9987), significantly decreases Group 3 MB MYC expression in both flank and intracranial growth in vivo. Human MB RNA-seq data show that EYA2 and MYC are significantly positively correlated, high EYA2 expression is significantly associated with a MYC transcriptional signature, and patients with high EYA2 and MYC expression have worse prognoses than those that do not express both genes at high levels.
Conclusions
Our data demonstrate that EYA2 is a critical regulator of MYC in Group 3 MB and suggest a novel therapeutic avenue to target this highly lethal disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, University of Colorado Anschutz Medical Campus (AMC), Aurora, Colorado, USA.
- Molecular Biology Graduate Program, University of Colorado AMC, Aurora, Colorado, USA.
- Cancer Biology Graduate Program, University of Colorado AMC, Aurora, Colorado, USA.
- Pharmacology Graduate Program, University of Colorado AMC, Aurora, Colorado, USA.
- Medical Scientist Training Program, University of Colorado AMC, Aurora, Colorado, USA.
- Integrated Physiology Graduate Program, University of Colorado AMC, Aurora, Colorado, USA.
ORCID-Profile: Arthur R Wolin, Stephen C Purdy, Sheera R Rosenbaum, Connor J Hughes, Marileila Varella-Garcia, Matthew D Galbraith, Dong Wang, Sujatha Venkataraman, Etienne Danis, Joaquin M Espinosa, Daniel L Gustafson, Heide L Ford
Förderung
- NINDS NIH HHS
- NIH HHS
- NCI NIH HHS
- NIH
Zitieren
APA
Wolin, A. R., Vincent, M. Y., Hotz, T., Purdy, S. C., Rosenbaum, S. R., Hughes, C. J., Hsu, J. Y., Oliphant, M. U. J., Armstrong, B., Wessells, V., Varella-Garcia, M., Galbraith, M. D., Pierce, A., Wang, D., Venkataraman, S., Danis, E., Veo, B., Serkova, N., Espinosa, J. M., …, & Ford, H. L. (2023). EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad128
Vancouver
Wolin AR, Vincent MY, Hotz T, Purdy SC, Rosenbaum SR, Hughes CJ, et al. EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression. Neuro-Oncology. 2023. doi:10.1093/neuonc/noad128
BibTeX
@article{Wolin2023,
author = {Wolin, Arthur R and Vincent, Melanie Y and Hotz, Taylor and Purdy, Stephen C and Rosenbaum, Sheera R and Hughes, Connor J and Hsu, Jessica Y and Oliphant, Michael U J and Armstrong, Brock and Wessells, Veronica and Varella-Garcia, Marileila and Galbraith, Matthew D and Pierce, Angela and Wang, Dong and Venkataraman, Sujatha and Danis, Etienne and Veo, Bethany and Serkova, Natalie and Espinosa, Joaquin M and Gustafson, Daniel L and Vibhakar, Rajeev and Ford, Heide L},
title = {EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression},
journal = {Neuro-Oncology},
year = {2023},
doi = {10.1093/neuonc/noad128}
}
EUVIMED